Hermanth Varghese
President chez VENUS CONCEPT INC.
Fortune : 11 517 $ au 31/03/2024
Profil
Hermanth Jacob Varghese is currently the President & Chief Operating Officer at Venus Concept, Inc. He previously worked as a Director at Trillium Therapeutics, Inc., a Non-Executive Director at Litha Healthcare Group Ltd., and a Vice President-Business Development at Biovail Corp.
From 2014 to 2016, he served as the Executive VP-Corporate Development & Strategy at Endo International Plc.
He also held positions as an Assistant Vice President at MedTech Partners, Inc. and Medical Discovery Management Corp.
From 2009 to 2014, he was the Senior VP-Corporate Development at Bausch Health Cos., Inc. Additionally, he worked as the Senior Vice President-Strategy & Operations at HLS Therapeutics, Inc. from 2017 to 2022.
He was also the General Manager at Bausch + Lomb Corp.
from 2009 to 2014.
Dr. Varghese obtained undergraduate and doctorate degrees from the University of Western Ontario.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VENUS CONCEPT INC
0,26% | 24/03/2023 | 16 667 ( 0,26% ) | 11 517 $ | 31/03/2024 |
Postes actifs de Hermanth Varghese
| Sociétés | Poste | Début |
|---|---|---|
| VENUS CONCEPT INC. | President | 17/10/2022 |
Anciens postes connus de Hermanth Varghese
| Sociétés | Poste | Fin |
|---|---|---|
| HLS THERAPEUTICS INC. | Chief Operating Officer | 01/01/2022 |
| ENDO INTERNATIONAL PLC | Corporate Officer/Principal | 31/12/2016 |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Director/Board Member | 06/06/2014 |
| BAUSCH + LOMB CORPORATION | Corporate Officer/Principal | 01/01/2014 |
| BAUSCH HEALTH COMPANIES INC. | Corporate Officer/Principal | 01/01/2014 |
Formation de Hermanth Varghese
| University of Western Ontario | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| ENDO INTERNATIONAL PLC | Health Technology |
| BAUSCH HEALTH COMPANIES INC. | Health Technology |
| HLS THERAPEUTICS INC. | Health Technology |
| VENUS CONCEPT INC. | Health Technology |
| BAUSCH + LOMB CORPORATION | Health Technology |
| Entreprise privées | 5 |
|---|---|
Biovail Corp.
 Biovail Corp. Pharmaceuticals: MajorHealth Technology Biovail Corp. develops and manufactures pharmaceutical products. The company provides different types of products which include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. Its products are used for cardiovascular disease, central nervous system disorders, pain management and other niche areas. It was founded on March 29, 1994 and is headquartered in Mississauga, Canada. | Health Technology |
MedTech Partners, Inc.
 MedTech Partners, Inc. Investment ManagersFinance MedTech Partners, Inc. provides investment services. The firm offers investment services to develop and commercialize early-stage biomedical innovations. The company is headquartered in Nepean, Ontario. | Finance |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
Medical Discovery Management Corp.
 Medical Discovery Management Corp. Investment ManagersFinance Medical Discovery Management Corp. (MDMC) is a venture capital fund manager located in Toronto. They are a subsidiary of JovFunds Management, Inc. Their ultimate parent is Jovian Capital Corp. (Toronto: JOV.TO) | Finance |
Litha Healthcare Group Ltd.
 Litha Healthcare Group Ltd. BiotechnologyHealth Technology Litha Healthcare Group Ltd. develops pharmaceutical products and medical devices. The firm distributes products in three main sectors of the South African healthcare industry. It operates through following divisions; Litha Pharma, Medical and Biotech. The company was founded by Selwyn Kahanovitz in 1992 and is headquartered in Johannesburg, South Africa. | Health Technology |
